Mouth Patents (Class 424/435)
  • Patent number: 10449139
    Abstract: Described herein are aqueous compositions comprising polymers, which deliver a polymer film to surfaces of the oral cavity to relieve dry mouth; and methods of preparing and using the same.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: October 22, 2019
    Assignee: Colgate-Palmolive Company
    Inventors: Paloma Pimenta, Marilou T. Joziak, Edward Joziak, Shira Pilch
  • Patent number: 10413512
    Abstract: A dust-reduced nicotine-containing granulate comprising a homogenous mixture of nicotine or a pharmaceutically acceptable nicotine derivative and an excipient, the granulate having a particle size of at least 150 ?m. Method for the preparation of a dust-reduced nicotine-containing granulate, and use of the nicotine-containing granulate for the preparation of pharmaceutical products.
    Type: Grant
    Filed: September 16, 2009
    Date of Patent: September 17, 2019
    Assignee: SIEGFRIED LTD.
    Inventor: Tillmann Roehrich
  • Patent number: 10342775
    Abstract: The present disclosure relates to emulsions for parenteral administration comprising 1000 to 5000, preferably 1500 to 3000 IU, vitamin A per ml, wherein the emulsions are free of polysorbates and polyoxyethylene/polyoxypropylene block copolymers. The present disclosure further relates to a method for manufacturing the compositions of the disclosure as well as to the use of the compositions of the disclosure.
    Type: Grant
    Filed: May 20, 2016
    Date of Patent: July 9, 2019
    Assignee: FRESENIUS KABI DEUTSCHLAND GMBH
    Inventors: Edmundo Brito De La Fuente, Crispulo Gallegos-Montes, Lida A. Quinchia-Bustamente, Telli Hekmatara, Michael Betz
  • Patent number: 10342646
    Abstract: A method of smoothing teeth by, for instance, filling in cracks, chips and eroded areas by applying calcium and/or casein and/or phosphate and a source of OH? ions thereto. The method optionally provides that very thin layer(s) of dental cement be interlaced with other applied materials, and that the results be maintained in contact with the teeth involved by application of a composition of matter that adheres to said teeth and holds the results in place, while allowing at least some permeation of saliva therethrough. The method can optionally involve application of a backing strip or tray or the like to secure the other materials in place, but this is not a requirement where the composition of matter is sufficiently securing.
    Type: Grant
    Filed: June 7, 2017
    Date of Patent: July 9, 2019
    Inventors: James D. Welch, Janet M. Wehrli
  • Patent number: 10335381
    Abstract: A stabilized formulation of triamcinolone acetonide in a bioadhesive base material is provided. The present invention further includes a method of producing a stabilized non-aqueous TAA formulation and methods of measuring the stability of such TAA formulations.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: July 2, 2019
    Assignee: University of Mississippi
    Inventors: Michael A Repka, Angela Sutterer
  • Patent number: 10265367
    Abstract: The present disclosure relates generally to oral compositions and methods for inhibiting the formation of plaque biofilm by salivary bacteria, and more particularly, to oral compositions comprising a combination of magnolia bark extract (MBE) and L-arginine, N?-lauroyl ethyl ester (LAE). The oral compositions are useful for improving oral health, including inhibiting the formation of plaque biofilm by salivary bacteria and reducing plaque adherence to teeth.
    Type: Grant
    Filed: September 12, 2016
    Date of Patent: April 23, 2019
    Assignee: WM. WRIGLEY JR. COMPANY
    Inventors: Michael W. Dodds, Minmin Tian, Taichi Inui, Lilian Ramirez, Marcelo B. Aspiras
  • Patent number: 10183044
    Abstract: The disclosure provides a composition for inhibiting thrombosis. The composition includes 5 to 25% by weight of Fish Oil, 15 to 55% by weight of Willow Bark Extract, and 0.2 to 5% by weight of Vitamin E.
    Type: Grant
    Filed: May 16, 2016
    Date of Patent: January 22, 2019
    Assignee: P Tech, LLC
    Inventors: Peter M. Bonutti, Justin E. Beyers, Tonya M. Bierman
  • Patent number: 10111832
    Abstract: Embodiments of the present invention provide an orodispersible tablet having a hardness of 30 to 80 N, and preferably 40 to 75 N, a brittleness less than 1% and preferably less than 0.5%, disintegrating in the mouth within 60 seconds and preferably within 40 seconds, comprising an active ingredient in the form of coated microcrystals or microgranules and a mixture of excipients chosen from a group comprising a diluent, a disintegrant, a sweetener, a binder, a levelling agent, a humectant or wetting agent, a lubricant, a flavoring agent, a dye, and mixtures thereof, said mixture of excipients preferably coming in the form of grains.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: October 30, 2018
    Assignee: ETHYPHARM
    Inventors: Isabelle Decorte, Edouard Gendrot, Yann Prevost
  • Patent number: 10092642
    Abstract: The present invention aims at providing a mucosal vaccine composition that can be administered to an intraoral mucous membrane, ocular mucous membrane, ear mucous membrane, genital mucous membrane, pharyngeal mucous membrane, respiratory tract mucous membrane, bronchial mucous membrane, pulmonary mucous membrane, gastric mucous membrane, enteric mucous membrane, or rectal mucous membrane, that is useful as a prophylactic or therapeutic agent for infectious diseases or cancers, and is capable of safely and effectively inducing the systemic immune response and mucosal immune response.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: October 9, 2018
    Assignee: NITTO DENKO CORPORATION
    Inventors: Masahiro Fukasaka, Mitsuhiko Hori, Katsuyuki Okubo, Daisuke Asari, Arimichi Okazaki, Eiji Kiyotoh, Kyohei Matsushita
  • Patent number: 10064905
    Abstract: Pharmaceutical preparations include at least one component that enhances sexual response and at least one other compound that enhances sexual sensitivity and pleasure. The component that enhances sexual response enhances blood flow to the genital region. Examples include compounds that dilate blood vessels, such as compounds that increase the amount of nitric oxide (NO) in the blood. The component that enhances sexual sensitivity and pleasure includes one or more cannabinoid compounds from the plant genus Cannabis. Examples include tetrahydrocannabinol (THC), the main psychoactive constituent of Cannabis, and cannabidiol (CBD), which is less or non-psychoactive and modulates THC activity. The ratio of THC/CBD can be selected depending on age, gender, physical health, and/or psychological condition of the user.
    Type: Grant
    Filed: November 11, 2014
    Date of Patent: September 4, 2018
    Assignee: Ilysm, LLC
    Inventor: Dennis M. Jenn
  • Patent number: 9986756
    Abstract: An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, exhausted tobacco fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: June 5, 2018
    Assignee: ALTRIA CLIENT SERVICES LLC
    Inventors: Feng Gao, Frank Scott Atchley, Gregory James Griscik, Christopher Joseph DiNovi, Phillip M. Hulan, James Arthur Strickland, Diane Gee
  • Patent number: 9937135
    Abstract: Described herein are compositions comprising capsaicin and methods of treating muscle cramping in a subject, comprising orally administering to the subject a composition comprising capsaicin and an excipient.
    Type: Grant
    Filed: August 4, 2014
    Date of Patent: April 10, 2018
    Assignee: Flex Pharma, Inc.
    Inventors: Bruce P. Bean, Donald MacKinnon, Roderick MacKinnon
  • Patent number: 9931183
    Abstract: An orthodontic correction device set up within an oral cavity of a patient. It includes a bone screw member that has a plate, the plate includes at least a positioning portion, and a surface of the plate includes at least a fixing member; at least a bone screw is in connection with at least a positioning portion of the bone screw member, and that is fixed by implanting into the oral cavity; at least a base body is assembled on a surface of the teeth and including a connecting portion; and at least an elastic member, a fixing end of the elastic member is assembled and fixed on the fixing member of the bone screw member, a functioning end of the elastic member is in mutual connection with the connecting portion of the base body, and an orthodontic correction force is formed between the fixing end and the functioning end.
    Type: Grant
    Filed: May 5, 2015
    Date of Patent: April 3, 2018
    Assignee: DENSMART DENTAL CO., LTD.
    Inventor: Yin Chao Yao
  • Patent number: 9925139
    Abstract: The present invention relates to glucocorticoid-containing pharmaceutical compositions or kits for use in acute emergency situations where acute glucocorticoid therapy is required. Notably, the invention relates to pharmaceutical compositions and kits that are designed to be administered by non-medically trained persons outside a hospital or another medical or clinical setting. The invention also relates to a method for treating a disorder requiring acute glucocorticoid therapy by providing a fast onset of action of a glucocorticoid.
    Type: Grant
    Filed: April 21, 2005
    Date of Patent: March 27, 2018
    Assignee: ACUCORT AB
    Inventors: Stanko Skrtic, Jörgen Johnsson, Hans Lennernäs, Thomas Hedner, Gudmundur Johannsson
  • Patent number: 9854830
    Abstract: An oral tobacco product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix and tobacco fibers embedded in the mouth-stable polymer matrix. The oral tobacco product can be formed by extruding a mixture of mouth-stable polymer and tobacco fibers.
    Type: Grant
    Filed: January 18, 2013
    Date of Patent: January 2, 2018
    Assignee: ALTRIA CLIENT SERVICES LLC
    Inventors: Feng Gao, Frank Scott Atchley, Gregory Griscik, Christopher Joseph DiNovi, Phillip M. Hulan, Diane Gee, Munmaya K. Mishra, James Arthur Strickland
  • Patent number: 9833498
    Abstract: Methods and combinations are provided for controlling the duration of action, in vivo, of matrix-degrading enzymes. The methods and combinations permit temporary in-vivo activation of matrix-degrading enzymes upon administration to the extra cellular matrix (or “ECM”). Matrix-degrading enzymes having a controlled duration of action can be used to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components.
    Type: Grant
    Filed: March 6, 2009
    Date of Patent: December 5, 2017
    Assignee: Halozyme, Inc.
    Inventors: Gilbert Keller, Gregory I. Frost
  • Patent number: 9763960
    Abstract: The invention relates to a pharmaceutical composition in the form of a system in film form for transmucosal administration of steroid hormones. An administration system for steroid hormones which dissolves in the mouth and which releases with a high bioavailability is disclosed. The administration system in film form dissolves in the mouth preferably in a period of less than 30 min, and the steroid hormone entering the bloodstream transmucosally from the administration system leads to a rapid rise in the concentration in the blood. It is thus possible to achieve a maximum concentration of this steroid hormone in the blood in a period of less than 60 min after administration.
    Type: Grant
    Filed: March 28, 2006
    Date of Patent: September 19, 2017
    Assignee: LTS Lohmann Theraple-Systeme AG
    Inventors: Markus Krumme, Albert Radlmaier, Sascha General, Michael Dittgen, Keith Jensen
  • Patent number: 9763878
    Abstract: A pharmaceutical composition which is Rapidly Dissolved in a mouth, comprising (a) agglomerate units which is consisted of a discontinuous phase comprising the first component; and a continuous phase comprising the second component; and (b) a pharmaceutically acceptable excipient, in which the pharmaceutical composition is characterized in that the first component is an effective ingredient exhibiting the pharmacological activity, and the second component is sugar or sugar alcohol is provided.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: September 19, 2017
    Assignees: COREPHARM CO., LTD., COREPHARMBIO CO., LTD.
    Inventors: Young Sam Goo, Jeong Tae Kim
  • Patent number: 9737488
    Abstract: The present invention pertains to a pharmaceutical composition comprising the compound of the formula (I) in a high concentration and at least one pharmaceutically acceptable excipient, the use of the composition for the treatment of hyper-proliferative diseases, such as cancer, either as a sole agent, or in combination with other anti-cancer therapies, and the process for preparing of said composition.
    Type: Grant
    Filed: February 22, 2006
    Date of Patent: August 22, 2017
    Assignee: Bayer HealthCare LLC
    Inventors: Fritz Schückler, Axel Wollenschläger
  • Patent number: 9724277
    Abstract: A method for decreasing dental hypersensitivity, including sizing a plurality of non-functionalized microbeads to be between 0.01 ?m to 3 ?m in diameter, suspending the plurality of non-functionalized microbeads in a fluid matrix to define a dental delivery composition, introducing the dental delivery composition into an oral cavity, introducing respective non-functionalized microbeads into a dental tubule, adhering respective functionalized microbeads each other and to the dental tubule to define an aggregate, and occluding the dental tubule with the aggregate.
    Type: Grant
    Filed: April 10, 2013
    Date of Patent: August 8, 2017
    Inventor: Robert L. Karlinsey
  • Patent number: 9687454
    Abstract: The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.
    Type: Grant
    Filed: January 6, 2016
    Date of Patent: June 27, 2017
    Assignee: Indivior UK Limited
    Inventors: Garry L. Myers, Samuel D. Hilbert, Bill J. Boone, Beuford Arlie Bogue, Pradeep Sanghvi, Madhusudan Hariharan
  • Patent number: 9677061
    Abstract: Provided are soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. Sialated and pegylated forms of the sHASEGPs also are provided. Methods of treatment by administering sHASEGPs and modified forms thereof also are provided.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: June 13, 2017
    Assignee: Halozyme, Inc.
    Inventors: Louis H. Bookbinder, Anirban Kundu, Gregory I. Frost
  • Patent number: 9675548
    Abstract: Rapidly dissolving, oral film preparations for rapid release of an active agent in the oral cavity, in particular, rapidly dissolving oral films comprising a nicotine active which achieve good transbuccal absorption and provide nicotine craving relief to an individual are disclosed herein.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: June 13, 2017
    Assignee: GlaxoSmithKline, LLC
    Inventor: Li-Lan Chen
  • Patent number: 9579295
    Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: February 28, 2017
    Assignee: NAL PHARMACEUTICAL GROUP LIMITED
    Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
  • Patent number: 9561182
    Abstract: A medicament composition for the administration to pets is provided. The composition generally includes a film, a medicament and a flavoring composition that renders the film palatable to a pet.
    Type: Grant
    Filed: August 18, 2004
    Date of Patent: February 7, 2017
    Assignee: CURE Pharmaceutical Corporation
    Inventor: R. Steven Davidson
  • Patent number: 9526600
    Abstract: The disclosure describes biodegradable stents and methods for selectively guided tissue regeneration in treating a periodontal defect adjacent to a root of a tooth. The biodegradable stents and methods have a coronal portion and a transverse portion or shelf, which reduce unwanted migration of gingival epithelium, gingival connective tissue, and soft tissue and enable the cementum and periodontal ligament cells to re-establish the periodontal ligament in a proper sequence resulting in a new periodontal attachment.
    Type: Grant
    Filed: July 20, 2010
    Date of Patent: December 27, 2016
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Susan J. Drapeau, Daniel Andrew Shimko, Kelly Brook Emerton
  • Patent number: 9492400
    Abstract: A composition for delivering an active agent to a patient. The composition includes a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core. The polymer may include covalently linked poly(ethylene glycol) chains, and the mucoadhesive coating may be selected to facilitate transfer of the particle through the intestinal mucosa. A molecular weight and cross-link density of the polymer may be selected such that the polymer core will decompose in a predetermined time interval. The fraction of the dose of the drug entering the system at circulation during the predetermined time interval may be between about 0.25% and about 25%. The composition may be formulated as a plurality of nanoparticles or microparticles that are combined with a pharmaceutically acceptable carrier to produce an edible or inhalable drug product.
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: November 15, 2016
    Assignees: Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Sangyong Jon, Omid C. Farokhazd, Robert S. Langer, Jianjun Cheng
  • Patent number: 9439999
    Abstract: The present invention discloses a composite collagen sponge and the preparation method thereof. The composite collagen sponge comprises collagen, cell growth factors, and a protecting agent, and has a water absorption capacity of more than 52 times. The preparation method includes a cation chromatographic purification step and a two-stage inactivation step consisting of organic solvent/detergent virus inactivation and dry heat virus inactivation. The composite collagen sponge obtained by the method of the present invention not only improves the safety and performance of the product in clinical applications, but also ensures the stability and the bioactivity throughout the effective life of the product.
    Type: Grant
    Filed: June 7, 2012
    Date of Patent: September 13, 2016
    Assignee: Harbin Peiqilong Biopharmaceutical Co., Ltd
    Inventor: Shanshan Wang
  • Patent number: 9421356
    Abstract: An integrated iontophoresis skin-worn patch and method for delivering a therapeutically effective amount of a corticosteroid drug compound in a systemically-safe and skin-safe manner for site-specific treatment of inflammation pain is disclosed.
    Type: Grant
    Filed: August 27, 2008
    Date of Patent: August 23, 2016
    Assignee: Teikoku Pharma USA, Inc.
    Inventors: Carter R. Anderson, Russell L. Morris, Robert Cohen, William V. Fowler
  • Patent number: 9357801
    Abstract: The invention relates to chewing gums for the delivery of nicotine, wherein the average pH in the mouth of individuals chewing the chewing gum, in the time period from 3 to 7 minutes from the onset of chewing, is within the interval of 8.5 to 9.
    Type: Grant
    Filed: October 19, 2011
    Date of Patent: June 7, 2016
    Assignee: Fertin Pharma A/S
    Inventors: Vivi Bjerre Jorgensen, My Ly Lao Stahl
  • Patent number: 9326952
    Abstract: The invention is intended to provide an adhesive patch which contains a drug except bisoprolol and which effectively inhibits the occurrence of oozing out or sticking out of the adhesive layer components from the exposed area of the adhesive layer of the adhesive patch during storage as well as the occurrence of oozing out of the drug from the adhesive layer thereby preventing the reduction in drug content. The support, the release liner and the adhesive layer constituting the adhesive patch each are formed to have a rectangular planar shape and the entire adhesive patch are formed to have a rectangular planar shape, and a protrudent part is formed on the support-side surface of the adhesive patch at a corner thereof. In addition, the adhesive patch may be formed to have a middle part and a peripheral part, and the protrudent part may be formed at a corner of the rectangular middle part.
    Type: Grant
    Filed: February 23, 2011
    Date of Patent: May 3, 2016
    Assignee: NITTO DENKO CORPORATION
    Inventors: Yoshihiro Iwao, Kensuke Matsuoka, Kazuhiro Aoyagi
  • Patent number: 9292977
    Abstract: A diagnostic tool and method are provided wherein a faulty part and its part number is determined based on a retrieved DTC for a specific vehicle. The part number may include the original manufacturer's number and a generic equivalent manufacturer's number (if available). The diagnostic tool can search a parts database of various parts suppliers for their pricing and location. The diagnostic tool can also provide suggested fixes to the user based on the retrieved DTC.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: March 22, 2016
    Assignee: Bosch Automotive Service Solutions Inc.
    Inventors: Thomas Bertosa, Michael Gessner, James Fish
  • Patent number: 9289196
    Abstract: A hemostatic device includes a dissolvable coating and a hemostatic substance enclosed within the coating. The device can have, for example, a generally spherical shape. The hemostatic substance can be particles that take any shape, such as spherical, flat sheets, cubes, or other regular or irregular shapes of any size or volume that can be used on or within a body.
    Type: Grant
    Filed: December 12, 2007
    Date of Patent: March 22, 2016
    Assignee: COOK MEDICAL TECHNOLOGIES LLC
    Inventor: Daniel J. Sirota
  • Patent number: 9290757
    Abstract: Methods for identifying modified proteases with modified substrate specificity or other properties are provided. The methods screen candidate and modified proteases by contacting them with a substrate, such as a serpin, an alpha macroglobulins or a p35 family protein or modified serpins and modified p35 family members or modified alpha macroglobulins, that, upon cleavage of the substrate, traps the protease by forming a stable complex. Also provided are modified proteases.
    Type: Grant
    Filed: May 18, 2012
    Date of Patent: March 22, 2016
    Assignee: Catalyst Biosciences, Inc.
    Inventor: Edwin L. Madison
  • Patent number: 9254294
    Abstract: The present invention provides a pharmaceutical composition for sublingual or buccal administration of actives with low to poor aqueous solubility, e.g. the hormone estradiol, which contains a solution of the active in a pharmaceutically acceptable solvent adsorbed or absorbed onto particles of a pharmaceutically acceptable carrier and methods of preparing and using the pharmaceutical composition.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: February 9, 2016
    Assignee: PHARMACEUTICAL PRODUCTIONS INC.
    Inventor: John McCarty
  • Patent number: 9119776
    Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: September 1, 2015
    Assignee: NAL Pharmaceuticals, Ltd.
    Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
  • Patent number: 9114075
    Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.
    Type: Grant
    Filed: June 19, 2014
    Date of Patent: August 25, 2015
    Assignee: NAL Pharmaceuticals, Ltd.
    Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
  • Patent number: 9114073
    Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: August 25, 2015
    Assignee: NAL Pharmaceuticals, Ltd.
    Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
  • Patent number: 9114074
    Abstract: Oral dosage forms as a biodegradable, water soluble film for delivering pharmaceutically active agents, to patients through insertion into the mouth of patient and methods for administering pharmaceutically active agents to patients by insertion into the mouth to provide selective uptake of said agents through the mucosa and thus avoiding the gastrointestinal tract.
    Type: Grant
    Filed: May 16, 2014
    Date of Patent: August 25, 2015
    Assignee: NAL Pharmaceuticals, Ltd.
    Inventors: Je Phil Ryoo, Chun Kwong Chu, Zheng Wang
  • Patent number: 9044500
    Abstract: An oral care composition is described for use in the treatment or alleviation of the symptoms of dry mouth comprising polyvinyl pyrrolidone (PVP) or a derivative thereof, an anionic mucoadhesive polymer and an orally acceptable carrier or excipient.
    Type: Grant
    Filed: July 29, 2005
    Date of Patent: June 2, 2015
    Assignees: GlaxoSmithKline Consumer Healthcare GmbH & Co KG, Glaxo Group Limited
    Inventors: Gertrud Kawa, Shireen Uppal, David Urquhart
  • Patent number: 9029423
    Abstract: The invention relates to pharmaceutical formulations, and more particularly to formulations containing cannabinoids for administration via a pump action spray. In particular, the invention relates to pharmaceutical formulations, for use in administration of lipophilic medicaments via mucosal surfaces, comprising: at least one lipophilic medicament, a solvent and a co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation and the formulation is absent of a self emulsifying agent and/or a fluorinated propellant.
    Type: Grant
    Filed: November 7, 2013
    Date of Patent: May 12, 2015
    Assignee: GW Pharma Limited
    Inventor: Brian Anthony Whittle
  • Patent number: 8986005
    Abstract: An oral care device is described for contacting or transferring a dental composition to the hard or soft surfaces of the teeth comprising a backing layer and a discontinuous pattern of a dentally therapeutic composition. A method of using said oral care device to effectuate an aesthetic or therapeutic treatment is also described, whereby the oral care device is placed against the surface of at least one oral cavity structure, the discontinuous pattern of dentally therapeutic composition is contacted with or transferred to said structure. The backing layer may be left in place during the treatment period, or optionally removed from the oral cavity while leaving the therapeutic composition in contact with the target structure.
    Type: Grant
    Filed: September 12, 2011
    Date of Patent: March 24, 2015
    Assignee: Discus Dental, LLC
    Inventor: R. Eric Montgomery
  • Patent number: 8979534
    Abstract: Provided is an acellular mammalian tooth-shaped scaffold including a compound that is chemotactic, osteogenic, dentinogenic, amelogenic, or cementogenic. Also provided is a method of replacing a tooth in the mouth of a mammal, where the tooth is absent and a tooth socket is present in the mouth at the position of the absent tooth. The method includes implanting an acellular scaffold having the shape of the missing tooth into the tooth socket. Additionally, a method of making a tooth scaffold is provided. The method includes synthesizing an acellular scaffold in the shape of a mammalian tooth and adding at least one compound that is chemotactic, osteogenic, dentinogenic, amelogenic, or cementogenic.
    Type: Grant
    Filed: June 17, 2010
    Date of Patent: March 17, 2015
    Assignee: The Trustees of Columbia University in the City of New York
    Inventor: Jeremy J. Mao
  • Patent number: 8980305
    Abstract: There is provided pharmaceutical compositions for the treatment of pain comprising a pharmacologically-effective amount of an opioid analgesic, or a pharmaceutically-acceptable salt thereof, presented in particulate form upon the surfaces of carrier particles comprising a pharmacologically-effective amount of an opioid antagonist, or a pharmaceutically-acceptable salt thereof, which carrier particles are larger in size than the particles of the opioid analgesic. The compositions are also useful in prevention of opioid abuse by addicts.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: March 17, 2015
    Assignee: Orexo AB
    Inventor: Anders Pettersson
  • Patent number: 8974813
    Abstract: A water-swellable linear polymer is made by reacting together a polyethylene oxide of number average molecular weight less than 4,000, an aliphatic diol, and a difunctional diisocyanate. Controlled release composition comprises the polymer together with an active agent. The polymer is able to take up pharmaceutically active agents of molecular weight 200 to 20,000.
    Type: Grant
    Filed: June 27, 2007
    Date of Patent: March 10, 2015
    Assignee: Ferring B.V.
    Inventors: Jukka Tuominen, Amaia Zurutuza, Mark Livingstone, Janet Anne Halliday
  • Publication number: 20150056268
    Abstract: The present invention relates to water-soluble films incorporating anti-tacking agents and methods of their preparation. Anti-tacking agents may improve the flow characteristics of the compositions and thereby reduce the problem of film adhering to a user's mouth or to other units of film. In particular, the present invention relates to edible water-soluble delivery systems in the form of a film composition including a water-soluble polymer, an active component selected from cosmetic agents, pharmaceutical agents, vitamins, bioactive agents and combinations thereof and at least one anti-tacking agent.
    Type: Application
    Filed: May 21, 2014
    Publication date: February 26, 2015
    Applicant: MonoSol Rx, LLC
    Inventors: Garry L. Myers, Pradeep Sanghvi, Andrew Philip Verrall, Vimala Francis, Laura Moss
  • Patent number: 8945606
    Abstract: A dissolving oral adhering disc (troche) with a dimple on at least one side to improve adhesion to hard convex surfaces in the mouth, including teeth, orthodontic braces, and gums (keratinized gingiva). The disc may be designed to prevent or treat a sore in the mouth opposite a tooth or brace and/or to release a medication into the mouth, to treat such as sore or to treat or prevent conditions elsewhere in the mouth or throat or stomach.
    Type: Grant
    Filed: October 10, 2008
    Date of Patent: February 3, 2015
    Assignee: OralHealth Corp.
    Inventor: Jeffrey T. Haley
  • Patent number: 8940271
    Abstract: The invention includes compositions for transmucosal administration to an animal comprising at least one active agent and a pharmaceutically acceptable carrier. A preferred active agent is selected from the group consisting of meloxicam, carprofen, enrofloxacin, clemastine, diphenhydramine, digoxin, levothyroxine, cyclosporine, ondansetron, lysine, zolpidem, propofol, nitenpyram, ivermectin, milbemycin, and pharmaceutically acceptable salts, solvates and esters thereof. In another embodiment, the invention includes methods of treating or preventing a condition in an animal comprising transmucosally administering a composition comprising a therapeutically or prophylactically effective amount of an active agent and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 15, 2011
    Date of Patent: January 27, 2015
    Assignee: Abbott Laboratories
    Inventors: Mark C. Heit, Antonio M. Benitz, Dennis F. Steadman, David M. Petrick
  • Patent number: 8940320
    Abstract: The invention relates to a dental implant, which comprises a coating at least in those surface areas that come into contact with hard and/or soft tissue when implanted. To ensure that the active ingredient contained in the coating (bisphosphonate) is released into the surrounding tissue or can act in the latter in a controlled manner at the correct speed, the coating is characterized in that it contains bisphosphonate, the respective pharmaceutically compatible salts or esters of the latter, in addition to at least one amphiphilic component, selected from the group containing branched or linear, substituted or unsubstituted, saturated or partially unsaturated C10-C30 alkyl-, alkenyl, alkylaryl-, aryl-, cycloalkyl-, alkylcycloalkyl-, alkylcycloaryl-carboxylates, -phosphates or -sulfates or mixtures thereof and/or a water-soluble ionic polymer component.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: January 27, 2015
    Assignee: Thommen Medical AG
    Inventors: Falko Schlottig, Matthias Schnabelrauch, Armin Rex Kautz
  • Patent number: 8936808
    Abstract: The invention is directed in part to oral dosage forms comprising a combination of an opioid agonist, acetaminophen and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: January 20, 2015
    Assignee: Purdue Pharma L.P.
    Inventors: Robert F. Kaiko, Robert D. Colucci